CRYSVITA

Product Overview

About CRYSVITA

CRYSVITA is a prescription medication containing the active ingredient burosamab, a recombinant fully human monoclonal antibody. It is used to treat adults and children with X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by low phosphate levels in the blood.

Key Benefits & Uses

• Treatment of X-linked hypophosphatemia (XLH) in adults and children
• Increases phosphate levels in the blood and bone mineral density
• Improves symptoms of XLH, such as short stature, bone pain, and muscle weakness

Active Ingredient & Action

CRYSVITA works by binding to and inhibiting the activity of fibroblast growth factor 23 (FGF23), a hormone that regulates phosphate levels in the body. By blocking FGF23, burosamab increases phosphate reabsorption in the kidneys and reduces phosphate excretion, leading to increased phosphate levels in the blood and bone mineral density.

Important Notes

CRYSVITA is administered via subcutaneous injection every two weeks. It is essential to follow the recommended dosing schedule and to have regular blood tests to monitor phosphate levels. Patients with a history of hypersensitivity reactions to burosamab or other monoclonal antibodies should not use CRYSVITA. Consult a healthcare professional for more information and to discuss potential side effects and interactions with other medications.